We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02030236
Recruitment Status : Unknown
Verified March 2014 by Bodychillz Ltd.
Recruitment status was:  Not yet recruiting
First Posted : January 8, 2014
Last Update Posted : March 4, 2014
Information provided by (Responsible Party):
Bodychillz Ltd

Brief Summary:

Cooling the whole body to 32-34 degrees Centigrade from the normal of around 37 degrees Centigrade for 24 hours has been shown to be an effective way of reducing damage to brain function after return of spontaneous circulation when someone has been resuscitated from cardiac arrest. Cardiac arrest is a form of heart attack where the heart stops pumping.

The device is a prototype cooling vest. The investigators anticipate that this will be useful in ambulances, helicopters and emergency departments where there is a need for a portable, safe, easy-to-use, inexpensive, external, effective, readily-controlled and single-patient use device able to reduce body temperature by at least 1 degree Centigrade an hour to initiate cooling. What the investigators are doing in these trials is to demonstrate that the investigators can cool people and to get the best design possible for patient use. That means some of the initial prototypes will not resemble what we expect the eventual device to look like. The investigators will be undertaking the initial trials on 30 normal volunteers.

Condition or disease Intervention/treatment Phase
Hypothermia. Device: Cooling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.
Study Start Date : March 2014
Estimated Primary Completion Date : May 2014
Estimated Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothermia

Arm Intervention/treatment
Experimental: Cooling Device: Cooling
Temperature reached Duration of exposure to cold.
Other Name: CAERvest prototype

Primary Outcome Measures :
  1. Reduction in core body temperature by 1 degree Centigrade. [ Time Frame: 1 hour. ]
    The cooling properties of the vest are under investigation, and this reduction is the primary outcome measure.

Secondary Outcome Measures :
  1. Skin condition. [ Time Frame: 3 days. ]
    As the cooling is performed by a cold vest applied directly to the skin we need to ensure that no skin damage is caused.

  2. ECG abnormalities. [ Time Frame: 3 hours. ]

    ECG abnormalities: ECG abnormalities are common after cardiac arrest, and have been noted in cooled patients after cardiac arrest. We will monitor the ECG for any abnormalities. The following will be noted but will not terminate the study:

    Bradycardia of less than 15 beats per minute below baseline. Unifocal ventricular ectopics. Unifocal atrial ectopics. Any other cardiac abnormality will cause immediate termination of the study and intervention to treat as necessary. A defibrillator will be available in the study room.

  3. Sepsis. [ Time Frame: 3 days. ]
    Sepsis: Increased rates of sepsis have been seen in intensive care units in patients who have received therapeutic hypothermia. We will enquire about sepsis symptoms in our follow-up contact.

  4. Skin condition. [ Time Frame: 3 days. ]
    Our aim is not to cause any skin damage to patients or volunteers. We will therefore inspect the skin after removing the vest or at any time before that if the volunteer expresses concern. We expect pallor of the skin during cooling and reddening during rewarming with some numbness and some discomfort, both during cooling and rewarming. We will regard any evidence of frostbite as a serious untoward injury (SUI) and this will result in suspension of the study and an investigation into the specific vest used and the general vest design and formulation. We regard this as a serious risk but highly unlikely in practice.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Human volunteers aged over 18. The upper age limit, as is standard for risk mitigation in such studies, is 35. The volunteer must have capacity to understand the trial and give informed consent to participate. If the volunteer's first language is not English we will make use of Sussex Interpreting Services, a professional interpreting service.

Exclusion Criteria:

Pregnancy. Any disclosed medical condition. Any medical condition detected on examination. Core temperature outside stated parameters.

We will ask the volunteer to confirm that they are otherwise healthy, taking no regular medication (except the oral contraceptive pill), are not using recreational drugs and have no significant past medical history, in particular cardiovascular disease of any sort, thyroid disease, diabetes mellitus or other metabolic disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02030236

Layout table for location contacts
Contact: Rowland L Cottingham, FRCS FCEM +44 1273 696955 rowley.cottingham@bodychillz.com

Layout table for location information
United Kingdom
CIRU, Royal Sussex County Hospital
Brighton, United Kingdom, BN2 5BE
Principal Investigator: Rowland L Cottingham, FRCS FCEM         
Sponsors and Collaborators
Bodychillz Ltd
Layout table for investigator information
Principal Investigator: Rowland L Cottingham, FRCS FCEM Brighton and Sussex Universities Hospital NHS Trust
Additional Information:
Layout table for additonal information
Responsible Party: Bodychillz Ltd
ClinicalTrials.gov Identifier: NCT02030236    
Other Study ID Numbers: CAERvest-001
First Posted: January 8, 2014    Key Record Dates
Last Update Posted: March 4, 2014
Last Verified: March 2014
Keywords provided by Bodychillz Ltd:
hypothermia, induced
heart arrest
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Temperature Changes